Genetic profiling of BRAF inhibitor-induced keratoacanthomas reveals no induction of MAP kinase pathway expression

Journal of Investigative Dermatology

Volumn 133, Issue 3, 2013, Pages 830-833

  Kulkarni, Rajan P ^a   Plaisier, Seema ^b   Ra, Seong H ^a   Li, Xinmin ^a   Lee, Delphine J ^b   Hillman, Joseph D ^a   Binder, Scott W ^a  

^a UCLA MEDICAL CENTER   (United States)

^b JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE INHIBITOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; VEMURAFENIB;

DISEASE COURSE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; KERATOACANTHOMA; LETTER; MICROARRAY ANALYSIS; MOLECULAR GENETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA;

EID: 84873709121     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2012.353     Document Type: Letter

References (12)

1. Bollag G, Hirth P, Tsai J et al. (2010) Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467: 596-9
2. Chapman PB, Hauschild A, Robert C et al. (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507-16
3. Clausen OP, Aass HC, Beigi M et al. (2006) Are keratoacanthomas variants of squamous cell carcinomas? A comparison of chromosomal aberrations by comparative genomic hybridization. J Invest Dermatol 126: 2308-15
4. Cribier B, Asch P, Grosshans E (1999) Differentiating squamous cell carcinoma from keratoacanthoma using histopathological criteria. Is it possible? A study of 296 cases. Dermatology 199: 208-12
5. Flaherty KT, Puzanov I, Kim KB et al. (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363: 809-19
6. Heidorn SJ, Milagre C, Whittaker S et al. (2010) Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140: 209-21
7. Joseph EW, Pratilas CA, Poulikakos PI et al. (2010) The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci USA 107: 14903-8
8. Nazarian R, Shi H, Wang Q et al. (2010) Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468: 973-7
9. Oberholzer PA, Kee D, Dziunycz P et al. (2012) RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol 30: 316-21
10. Packer LM, East P, Reis-Filho JS et al. (2009) Identification of direct transcriptional targets of (V600E)BRAF/MEK signalling in melanoma. Pigment Cell Melanoma Res 22: 785-98
11. Poulikakos PI, Zhang C, Bollag G et al. (2010) RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464: 427-30
12. Su F, Viros A, Milagre C et al. (2012) RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 366: 207-15